ArticleTropical medicine and health2026
The COVID-19 impact on nocturia epidemiology: a national health survey analysis.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionThe COVID-19 pandemic has significantly impacted disease burdens, yet updated nocturia epidemiological data remain limited. This study characterized age-sex-race disparities in nocturia prevalence and evaluated pandemic-related temporal changes.
methodsUsing NHANES data (2017-2023), this cross-sectional study included 10,946 adults (≥ 20 years). Primary outcomes were nocturia prevalence (≥ 1 and ≥ 2 nightly episodes). Analyses incorporated sampling weights and multivariable logistic regression.
resultsOverall weighted prevalence reached 71.9% for nocturia (≥ 1 time/night) and 31.2% for clinical nocturia (≥ 2 times/night). Post-pandemic surge was significant: nocturia increased from 70.0% to 75.3% (P = 0.002) and clinical nocturia from 28.5 to 36.0% (P < 0.001) (2017-2020 vs. 2021-2023). Young males showed the steepest clinical nocturia escalation (11.6-24.1%, P = 0.001), while middle-aged females experienced significant increases in overall nocturia (70.2-77.1%, P = 0.054). Racial disparities widened post-pandemic, with Hispanic populations demonstrating a 43.5% increase in clinical nocturia (26.9-38.6%, P < 0.001). Multivariable regression confirmed obesity as an independent risk factor (OR = 1.312, 95% CI 1.119-1.539, P = 0.002). Obesity-related exacerbation intensified during the pandemic: obese males experienced a 38.9% surge in nocturia (54.5-75.7%, P = 0.005) and 201% increase in clinical nocturia (10.4-31.3%, P = 0.007).
conclusionsNocturia prevalence escalated markedly post-pandemic, disproportionately affecting young and obese males. Targeted interventions addressing metabolic health and socioeconomic disparities are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.